Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Daniel Catenacci

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Catenacci, Daniel

Item TypeName
Concept Esophageal Neoplasms
Academic Article RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Academic Article Gastroesophageal cancer: focus on epidemiology, classification, and staging.
Academic Article Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.
Academic Article MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Academic Article It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma.
Academic Article Novel Targeted Therapies for Esophagogastric Cancer.
Academic Article Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Academic Article Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Academic Article Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Academic Article Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Academic Article Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Academic Article Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Academic Article Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Academic Article Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Academic Article Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
Academic Article Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Academic Article FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.
Academic Article Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Academic Article Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Academic Article Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
Academic Article Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

Search Criteria
  • Esophageal Neoplasms